Methylprednisolone sodium succinate and Transplant rejection - a phase IV clinical study of FDA data

Summary:

Transplant rejection is found among people who take Methylprednisolone sodium succinate, especially for people who are male, 50-59 old, have been taking the drug for < 1 month.

The phase IV clinical study analyzes which people take Methylprednisolone sodium succinate and have Transplant rejection. It is created by eHealthMe based on reports of 10,060 people who have side effects when taking Methylprednisolone sodium succinate from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.



On Jul, 04, 2022

10,060 people reported to have side effects when taking Methylprednisolone sodium succinate.
Among them, 48 people (0.48%) have Transplant rejection.


What is Methylprednisolone sodium succinate?

Methylprednisolone sodium succinate has active ingredients of methylprednisolone sodium succinate. eHealthMe is studying from 10,070 Methylprednisolone sodium succinate users for its effectiveness, alternative drugs and more.

What is Transplant rejection?

Transplant rejection (a transplant material is not worked) is found to be associated with 896 drugs and 596 conditions by eHealthMe.

Number of Methylprednisolone sodium succinate and Transplant rejection reports submitted per year:

Could Methylprednisolone sodium succinate cause Transplant rejection?

Time on Methylprednisolone sodium succinate when people have Transplant rejection *:

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Transplant rejection when taking Methylprednisolone sodium succinate *:

  • female: 21.28 %
  • male: 78.72 %

Age of people who have Transplant rejection when taking Methylprednisolone sodium succinate *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 4.44 %
  • 20-29: 24.44 %
  • 30-39: 15.56 %
  • 40-49: 8.89 %
  • 50-59: 28.89 %
  • 60+: 17.78 %

Common drugs people take besides Methylprednisolone sodium succinate *:

  1. Ciclosporin: 9 people, 18.75%
  2. Sulfamethoxazole And Trimethoprim: 9 people, 18.75%
  3. Bactrim: 7 people, 14.58%
  4. Cellcept: 6 people, 12.50%
  5. Simulect: 6 people, 12.50%
  6. Omeprazole: 6 people, 12.50%
  7. Polaramine: 5 people, 10.42%
  8. Tacrolimus: 5 people, 10.42%
  9. Ursodeoxycholic Acid: 4 people, 8.33%
  10. Hydrocortisone Sodium Succinate: 4 people, 8.33%

Common side effects people have besides Transplant rejection *:

  1. Drug Ineffective: 7 people, 14.58%
  2. Antimitochondrial Antibody Positive: 6 people, 12.50%
  3. Cytomegalovirus Infection: 6 people, 12.50%
  4. Hepatitis C: 5 people, 10.42%
  5. Fever: 4 people, 8.33%
  6. Pneumonia: 4 people, 8.33%
  7. Pancreatitis Necrotising (inflammation of the pancreas cause death of tissue in pancreas): 3 people, 6.25%
  8. Renal Failure Acute (rapid kidney dysfunction): 3 people, 6.25%
  9. Diarrhea: 3 people, 6.25%
  10. Renal Tubular Necrosis (death of kidney tubules): 3 people, 6.25%

Common conditions people have *:

  1. Immunodeficiency Disorders: 16 people, 33.33%
  2. Hepatitis C: 4 people, 8.33%
  3. High Blood Pressure: 4 people, 8.33%
  4. Hyperuricaemia (level of uric acid in the blood that is abnormally high): 3 people, 6.25%
  5. Pulmonary Tuberculosis (lungs tuberculosis): 2 people, 4.17%
  6. Gastritis - Chronic (long lasting inflammation of stomach): 2 people, 4.17%
  7. Osteoporosis (bones weak and more likely to break): 2 people, 4.17%
  8. Hyperphosphataemia (electrolyte disturbance in which there is an abnormally elevated level of phosphate in the blood): 2 people, 4.17%
  9. Glomerulonephritis Chronic (long lasting group of conditions that affect parts of the kidneys called glomeruli): 1 person, 2.08%
  10. Gastritis (inflammation of stomach): 1 person, 2.08%

* Approximation only. Some reports may have incomplete information.

Do you take Methylprednisolone sodium succinate and have Transplant rejection?

Check whether Transplant rejection is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of Methylprednisolone sodium succinate:

Transplant rejection treatments and more:

COVID vaccines that are related to Transplant rejection:

How severe was Transplant rejection and when was it recovered:

Expand to all the drugs that have ingredients of methylprednisolone sodium succinate:

Common drugs associated with Transplant rejection:

All the drugs that are associated with Transplant rejection:

Common conditions associated with Transplant rejection:

All the conditions that are associated with Transplant rejection:

How the study uses the data?

The study uses data from the FDA. It is based on methylprednisolone sodium succinate (the active ingredients of Methylprednisolone sodium succinate) and Methylprednisolone sodium succinate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: